ArticleJournal of clinical immunology1991
Light-chain ratio of serum IgA1 in IgA nephropathy.
Article in Journal of clinical immunology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Trial
- The role of mucosal immune dysregulation in the pathogenesis of immunoglobulin A nephropathy.Frontiers in immunology · 2026Review
- IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease.Frontiers in immunology · 2023Review
- A rare case of Immunoglobulin A dominant post-infectious glomerulonephritis (IgA PIGN) in a young patient.BMC nephrology · 2022Article
- New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.Kidney international · 2015Review
- Increase of both circulating Th1 and Th2 T lymphocyte subsets in IgA nephropathy.Clinical and experimental immunology · 1994Article
- Pathogenesis of idiopathic IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 1993Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with primary IgA nephropathy have deposits of IgA1 in their kidneys and increased IgA1 in circulation. We had previously shown that IgA nephritic patients displayed a unique immunological response characterized by a predominance of IgA with lambda chain in glomerular deposits and in circulation. We have now studied the kappa/lambda (kappa/lambda) ratio of serum IgA1 in 21 IgA nephritic patients at quiescence, with 11 patients investigated during exacerbation as well. A novel enzyme-linked immunosorbent assay was used with monoclonal mouse anti-human IgA1 as the solid-phase capture antibody and peroxidase-labeled anti-human kappa and lambda antibodies as tracers. The ratio of serum IgA1 to total IgA (mean +/- SD) was significantly higher in patients (90.1 +/- 8.2% at quiescence, P less than 0.01; 88.7 +/- 8.1% during exacerbation, P less than 0.02) than in 20 healthy age- and sex-matched controls (80.0 +/- 9.8%). Furthermore, serum IgA1 kappa/lambda ratios were significantly lower in patients (1.02 +/- 0.27 at quiescence, P less than 0.01; 0.93 +/- 0.16 during exacerbation, P less than 0.01) than in controls (1.31 +/- 0.30). These findings indicate a predominance of lambda light-chain IgA1 in the serum of IgA nephritic patients. However, no difference in IgA1 kappa/lambda ratio was observed in these patients at quiescence and during exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.